Back to discover
Disease

Arterial Occlusive Diseases

Late-stage therapeutic developmentEmerging research
MeSHArterial Occlusive Diseases
1
Publications
11
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Research2020-01-01Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2028.
Upcoming Milestones
Clinical Milestones2View
Results expected 1
Recently completed 1
Activity timeline2

Clinical trials

8 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
11
All trials
2
Active
6
Late-stage
6
Completed
Late-stage studies

A Randomized, Multicenter, Open-label, Parallel, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients Having Intermittent Claudication Among Chronic Artery Occlusive Disease

Phase 4 · Completed · Yuhan Corporation

Phase 3, Multicenter, Multi-National, Randomized, Partial Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion

Phase 3 · Completed · ARCA Biopharma, Inc.

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Phase 3 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Phase 3 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.

Phase 3 · Completed · Sanofi

Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)

Phase 3 · Terminated · ARCA Biopharma, Inc.
Recently completed

A Randomized, Multicenter, Open-label, Parallel, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients Having Intermittent Claudication Among Chronic Artery Occlusive Disease

Phase 4 · Completed · Yuhan Corporation

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)

Phase 2 · Completed · Tufts Medical Center

Phase 3, Multicenter, Multi-National, Randomized, Partial Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion

Phase 3 · Completed · ARCA Biopharma, Inc.

A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.

Phase 3 · Completed · Sanofi

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Phase 3 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

Cholesterol-Lowering Atherosclerosis Study (CLAS)

Phase 3 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2020 · 259 cites
Recent publications

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2020 · 259 cites
Major themes2
  • Betacoronavirus1
  • Pandemics1
Leading journals1
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis1
Leading researchers2
  • Makris M1
  • Miesbach W1
Affiliations (unnormalised)3
  • Department of Haemostaseology and Hemophilia Center1
  • Sheffield Haemophilia and Thrombosis Centre1
  • University of Sheffield1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.

Identifiers
MeSHArterial Occlusive Diseases
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.